[Asia Economy Reporter Minji Lee] Engchem Life Sciences announced on the 17th that it has decided on a paid-in capital increase worth 316.4 billion KRW through a rights offering to shareholders followed by a general public offering of unsubscribed shares.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
